Brief: Larimar Therapeutics Q3 Net Income USD -15.499 Million
Oct 30 (Reuters) - Larimar Therapeutics Q3 income from operations USD -18.264 million. * Q3 operating expenses USD 18.264 million * Q3 basic EPS USD -0.24
Recent news on Larimar Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Larimar tumbles as safety concerns resurface in rare disease drug study update
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-SpaceX, Charter, Gulfport Energy
Larimar tumbles as safety concerns resurface in rare disease drug study update